Breakthroughs in biomarkers for amyloid (A), tau (T), and neurodegeneration (N) have advanced the prospects of accurate Alzheimer’s disease (AD) diagnosis. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.